Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 14/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 3/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3459216 | 0.85 | PTGER2 (0.34) | PTGER2KEAP1NFE2L2F2 | |
| SCHEMBL17472571 | 0.84 | F2 (0.33) | F2 | |
| SCHEMBL533871 | 0.83 | PTGER2 (0.35) | PTGER2F2 | |
| SCHEMBL533518 | 0.83 | SLC1A3 (0.37) | PTGER2F2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL3458751 | 0.81 | PTGER2 (0.46) | PTGER2KEAP1NFE2L2F2 | |
| SCHEMBL13571491 | 0.81 | TP53 (0.34) | F2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL13571347 | 0.80 | PTGER2 (0.43) | PTGER2F2 | |
| SCHEMBL3459165 | 0.80 | PTGER2 (0.38) | PTGER2F2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL533647 | 0.80 | PTGER2 (0.41) | PTGER2F2 | |
| SCHEMBL12983336 | 0.79 | PTGER2 (0.41) | PTGER2F2SLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676720-B2 | Substituted biaryl compound | UBE INDUSTRIES, LTD. (JP) | 2017-06-13 | — | — | US | disclosed |
| EP-3042656-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PULMONARY DISEASE | UBE Industries, Ltd. (JP) | 2016-07-13 | — | — | EP | disclosed |
| US-20160060221-A1 | SUBSTITUTED BIARYL COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2016-03-03 | — | — | US | disclosed |
| EP-2980075-A1 | SUBSTITUTED BIARYL COMPOUND | UBE Industries, Ltd. (JP) | 2016-02-03 | — | — | EP | disclosed |
| EP-2415763-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | UBE INDUSTRIES (JP) | 2016-01-27 | — | — | EP | disclosed |
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2014-04-24 | — | — | US | disclosed |
| EP-2476668-B1 | ANILINE COMPOUNDS | UBE INDUSTRIES (JP) | 2013-11-06 | — | — | EP | disclosed |
| EP-2520570-A1 | AMINOPYRIDINE COMPOUND | Ube Industries, Ltd. (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-20120259123-A1 | AMINOPYRIDINE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2012-10-11 | — | — | US | disclosed |
| US-20120226036-A1 | SUBSTITUTED CARBONYL COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| EP-2476678-A1 | SUBSTITUTED CARBONYL COMPOUNDS | Ube Industries, Ltd. (JP) | 2012-07-18 | — | — | EP | disclosed |
| EP-2476668-A1 | ANILINE COMPOUNDS | Ube Industries, Ltd. (JP) | 2012-07-18 | — | — | EP | disclosed |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE CORPORATION (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2264009-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | Ube Industries, Ltd. (JP) | 2010-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120226036-A1 | SUBSTITUTED CARBONYL COMPOUND | PTGER2, PTGER1, LTB4R2 | PTGER2 1/4885KEAP1 173/4885NFE2L2 140/4885 |
| US-20160060221-A1 | SUBSTITUTED BIARYL COMPOUND | FIBP, FGF2, FGFR2 | PTGER2 2670/4885KEAP1 524/4885NFE2L2 654/4885 |
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | PTGER2 1/4885KEAP1 1064/4885NFE2L2 620/4885 |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | PTGER2 1/4885KEAP1 1210/4885NFE2L2 625/4885 |
| US-20120259123-A1 | AMINOPYRIDINE COMPOUND | PTGIS, QDPR, PTGIR | PTGER2 59/4885KEAP1 1212/4885NFE2L2 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.